US009119793B1

(12) **United States Patent**
Bakan et al.

(10) **Patent No.: US 9,119,793 B1**
(45) **Date of Patent: Sep. 1, 2015**

(54) **GASTRORETENTIVE DOSAGE FORMS FOR DOXYCYCLINE**

(75) Inventors: **Douglas A. Bakan**, San Diego, CA (US); **Waranush Jitpraphai**, Chandler, AZ (US); **Steven B. Newhard**, Scottsdale, AZ (US); **Mitchell S. Wortzman**, Scottsdale, AZ (US)

(73) Assignee: **Medicis Pharmaceutical Corporation**, Scottsdale, AZ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/536,052**

(22) Filed: **Jun. 28, 2012**

Related U.S. Application Data

(60) Provisional application No. 61/501,888, filed on Jun. 28, 2011, provisional application No. 61/508,459, filed on Jul. 15, 2011, provisional application No. 61/508,468, filed on Jul. 15, 2011, provisional application No. 61/508,484, filed on Jul. 15, 2011, provisional application No. 61/508,158, filed on Jul. 15, 2011, provisional application No. 61/508,338, filed on Jul. 15, 2011.

(51) **Int. Cl.**
A61K 35/14 (2015.01)
A61K 9/24 (2006.01)

(52) **U.S. Cl.**
CPC ***A61K 9/209*** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,952,402	A	8/1990	Sparks et al.
5,000,886	A	3/1991	Lawter et al.
5,051,262	A	9/1991	Panoz et al.
5,122,519	A	6/1992	Ritter
5,354,556	A	10/1994	Sparks et al.
5,516,531	A	5/1996	Makino et al.
5,538,954	A	7/1996	Koch et al.
5,780,055	A	7/1998	Habib et al.
5,789,395	A	8/1998	Amin et al.
5,919,775	A	7/1999	Amin et al.
6,077,533	A	6/2000	Oshlack et al.
6,080,426	A	6/2000	Amey et al.
6,193,994	B1	2/2001	Lee et al.
6,245,350	B1	6/2001	Amey et al.
6,340,475	B2	1/2002	Shell et al.
6,497,901	B1	12/2002	Royer
6,635,280	B2	10/2003	Shell et al.
6,638,532	B2	10/2003	Rudnic et al.
6,730,320	B2	5/2004	Rudnic et al.
6,958,161	B2	10/2005	Hayes et al.
7,008,631	B2	3/2006	Ashley
7,014,858	B2	3/2006	Ashley
7,201,923	B1	4/2007	van Lengerich
7,211,267	B2	5/2007	Ashley
7,232,572	B2	6/2007	Ashley
7,485,319	B2	2/2009	deVries et al.
7,749,532	B2	7/2010	Chang et al.
7,910,128	B2	3/2011	Chang et al.
7,939,570	B2	5/2011	Raul et al.
7,951,398	B2	5/2011	Dietrich et al.
7,951,403	B2	5/2011	Friesen et al.
7,976,870	B2	7/2011	Berner et al.
7,976,871	B2	7/2011	Vaya et al.
8,052,983	B2	11/2011	Ashley
8,071,075	B2	12/2011	Reed et al.
8,088,726	B2	1/2012	Yamamoto et al.
8,114,062	B2	2/2012	Muni et al.
8,114,385	B2	2/2012	Tamarkin et al.
8,133,510	B2	3/2012	Bartholomaeus et al.
8,137,684	B2	3/2012	Desai et al.
8,192,749	B2	6/2012	Ashley
8,202,912	B2	6/2012	Curatolo et al.
8,206,740	B2	6/2012	Chang et al.
2002/0044968	A1	4/2002	van Lengerich
2003/0077301	A1	4/2003	Maibach et al.
2003/0091630	A1	5/2003	Louie-Helm et al.
2003/0104052	A1	6/2003	Berner et al.
2003/0133985	A1	7/2003	Louie-Helm et al.
2003/0180362	A1	9/2003	Park et al.
2003/0211156	A1	11/2003	Dansereau et al.
2004/0115261	A1	6/2004	Ashley
2004/0147492	A1	7/2004	Ashley
2004/0185097	A1	9/2004	Kannan et al.
2004/0185105	A1	9/2004	Berner et al.
2004/0228915	A1	11/2004	Noack et al.
2005/0037071	A1	2/2005	Cao et al.
2005/0049210	A1	3/2005	Murthy et al.
2005/0152975	A1	7/2005	Nakagami et al.
2005/0266077	A1	12/2005	Royer

(Continued)

FOREIGN PATENT DOCUMENTS

WO	WO 95/31972	A1	11/1995
WO	WO 98/09597	A2	3/1998

(Continued)

OTHER PUBLICATIONS

Co-pending U.S. Appl. No. 13/536,052 inventors Bakan, D.A., et al., filed Jun. 28, 2012 (Filed With Request For Non-Publication).

(Continued)

Primary Examiner — Snigdha Maewall

(74) *Attorney, Agent, or Firm* — John E. Thomas, Esq.; Harter Secrest & Emery LLP

(57) **ABSTRACT**

The present disclosure relates to dosage forms, e.g., swell, float and bioadhesive, and methods that enhance the absorption of doxycycline in the gastrointestinal tract. The oral dosage forms control the spatial and temporal delivery of doxycycline in the gastrointestinal tract. This controlled spatial and temporal delivery provides a site and rate of release, respectively, of the doxycycline into the gastrointestinal tract that enhances the amount of the doxycycline absorbed into the bloodstream.

11 Claims, No Drawings